MedTrace Logo

Genetic Biomarker Discovery for Metastatic Prostate Cancer

NCT03228810 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4

Last updated 2019-05-09

No results posted yet for this study

Summary

Biomarkers from circulating cell-free tumor DNA in peripheral blood will identify patients with metastatic prostate cancer diagnosed with C11 choline PET/CT who will benefit from metastasis-directed radiation, ablative therapies, and/or surgery. Tissue and blood will be collected before treatment. If patients receive androgen deprivation, then blood will be collected after neoadjuvant androgen deprivation but before radiation, ablative therapies, or surgery. Subsequent samples will be obtained at 3 months and 6 months following treatment, after which no further patient contact will occur.

Conditions

Interventions

OTHER

Blood draw

(2) 10 mL tubes will be collected

PROCEDURE

Tissue biopsy

Tissue biopsy of metastatic tissue if undergoing clinical care-directed biopsy

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-02
Primary Completion
2019-04-09
Completion
2019-04-09

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03228810 on ClinicalTrials.gov